Clinical Lymphoma Myeloma & Leukemia
Scope & Guideline
Exploring Innovations in Blood Cancer Treatment
Introduction
Aims and Scopes
- Clinical Trials and Treatment Protocols:
The journal publishes studies related to clinical trials, particularly those evaluating the efficacy and safety of new therapies for hematological malignancies, including various combinations of chemotherapy, immunotherapy, and targeted therapies. - Patient Outcomes and Quality of Life:
Research focusing on the clinical outcomes of patients undergoing treatment for blood cancers, including survival rates, quality of life assessments, and the impact of treatment on patient well-being, is a core area of interest. - Molecular and Genetic Research:
The journal highlights studies that explore the molecular and genetic underpinnings of hematological malignancies, including the identification of biomarkers for diagnosis, prognosis, and treatment response. - Epidemiology and Health Disparities:
It addresses the epidemiological aspects of hematological malignancies, including studies on incidence, prevalence, and disparities in treatment access and outcomes among different populations. - Innovative Therapies and Novel Approaches:
Focus on emerging therapies, including CAR-T cell therapies, bispecific antibodies, and other novel agents, as well as their mechanisms of action and potential to improve patient outcomes.
Trending and Emerging
- CAR-T Cell Therapies and Bispecific Antibodies:
There is a growing body of research on CAR-T cell therapies and bispecific antibodies, particularly in their application for treating relapsed and refractory multiple myeloma and other hematological malignancies. - Minimal Residual Disease (MRD) Monitoring:
The focus on MRD as a prognostic marker is increasing, with studies exploring its implications for treatment decisions and patient management, particularly in multiple myeloma and acute lymphoblastic leukemia. - Health Disparities and Access to Care:
Emerging research emphasizes the importance of understanding health disparities in hematological malignancies, particularly regarding treatment access and outcomes among diverse populations. - Patient-Reported Outcomes and Quality of Life:
There is a heightened interest in assessing patient-reported outcomes and quality of life, reflecting a shift towards patient-centered care in the management of hematological malignancies. - Integration of Genomic and Proteomic Data:
The integration of genomic and proteomic analyses to inform treatment choices and understand disease mechanisms is gaining traction, leading to more personalized treatment approaches.
Declining or Waning
- Traditional Chemotherapy Regimens:
There is a noticeable decrease in studies centered around traditional chemotherapy regimens as newer targeted therapies and immunotherapies gain prominence in treatment protocols. - Longitudinal Studies of Established Treatments:
Long-term studies evaluating the efficacy of established treatments such as older chemotherapy agents have become less frequent as the focus shifts towards innovative therapies and combination regimens. - Basic Science Studies Without Clinical Relevance:
Research that does not directly translate into clinical applications or lacks immediate relevance to patient care appears to be waning, as there is a stronger emphasis on studies that can lead to actionable insights in clinical practice. - Palliative Care Studies:
The volume of research specifically addressing palliative care approaches for hematological malignancies seems to have decreased, possibly overshadowed by the focus on curative and novel treatment strategies. - Single-Agent Studies:
The exploration of single-agent therapies is less common as the field increasingly favors combination therapies that leverage synergistic effects to enhance treatment efficacy.
Similar Journals
Blood and Lymphatic Cancer-Targets and Therapy
Transforming Cancer Treatment Through Open AccessBlood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.
LEUKEMIA RESEARCH
Transforming insights into impactful clinical applications.Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.
BREAST
Empowering oncology with innovative insights.BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.
Thoracic Cancer
Pioneering discoveries in thoracic health.Thoracic Cancer is a distinguished open-access journal published by WILEY, dedicated to advancing the field of thoracic oncology. Since its establishment in 2010, the journal has emerged as a crucial platform for the dissemination of innovative research and clinical studies relating to lung cancer and other thoracic malignancies. With a commendable impact reflected in its 2023 Q2 rankings in the categories of Medicine (Miscellaneous), Oncology, and Pulmonary and Respiratory Medicine, the journal features high-quality articles that are vital for researchers, clinicians, and students aspiring to enhance their understanding of thoracic cancers. Operating out of Australia, Thoracic Cancer has embraced a commitment to open access since 2015, ensuring that vital research is readily available to a global audience. The journal's rigorous peer-review process and emphasis on novel findings make it an indispensable resource for professionals seeking to stay at the forefront of this rapidly evolving field.
BLOOD
Elevating Excellence in Hematological Studies.BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.
Blood Advances
Shaping the Landscape of Hematology ResearchBlood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.
International Journal of Clinical Oncology
Connecting Researchers to Transform Patient OutcomesInternational Journal of Clinical Oncology, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing research and clinical practices in the fields of oncology, hematology, and surgery. With its impact factor reflecting its significance and reach in the academic community, this journal serves as a solid platform for researchers, professionals, and students to share and disseminate groundbreaking discoveries and methodologies. Notably, it has secured prestigious rankings in the Q1 category in Medicine (miscellaneous) and Surgery, and Q2 in Hematology and Oncology, illustrating its prominent position in the medical literature. The journal's comprehensive scope addresses pivotal clinical issues from 1996 through 2024, further solidifying its relevance in the ever-evolving landscape of cancer research. Despite not offering open access, the depth and quality of research articles ensure that vital information remains accessible to those committed to improving clinical outcomes in oncology. With a focus on innovative treatments and patient care, the International Journal of Clinical Oncology embodies a commitment to fostering excellence in medical research.
Hemato is a pioneering open-access journal dedicated to the field of hematology, published by the esteemed MDPI from its base in Basel, Switzerland. Launched in 2020, this journal aims to provide a platform for researchers, clinicians, and professionals to share significant findings and advancements in blood-related disciplines over a converged timeframe until 2024. With a commitment to disseminating high-quality research, Hemato seeks to foster collaboration and innovation in hematological studies, showcasing original articles, reviews, and clinical studies that contribute to expanding knowledge in this vital area. As an open-access journal, it promotes accessible scholarship, ensuring that groundbreaking research reaches a broad audience, thereby enhancing the impact on the global health community.
ACTA HAEMATOLOGICA
Connecting Experts in Hematology for Global ImpactACTA HAEMATOLOGICA, published by KARGER, is a prestigious journal established in 1948, dedicated to the field of hematology and related medical sciences. With an ISSN of 0001-5792 and an E-ISSN of 1421-9662, this journal stands out with a Q2 ranking in both Hematology and Miscellaneous Medicine categories as of 2023. Researchers and professionals can benefit from its high-quality peer-reviewed articles, contributing to a more profound understanding and advancement of hematological practices. Although it does not offer open access options, ACTA HAEMATOLOGICA remains an essential resource for researchers in Switzerland and worldwide, providing critical insights and fostering discourse among academic and clinical communities. The journal's address is located in the heart of Basel, Switzerland, ensuring its robust connection to European medical research networks. With a firm commitment to excellence, this publication plays a vital role in disseminating knowledge, guiding future innovations in the field.
Blood Cancer Discovery
Illuminating the Path to Understanding Blood MalignanciesBlood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.